Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hasmann

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Letters|September 15, 1994
Preclinical data for DroloxifeneM Hasmann, B Rattel, R Löser
Anticancer Research|November 11, 2006
Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpressionT Friess, W Scheuer, M Hasmann
Pharmacology & Therapeutics|January 14, 2014
Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluationK Wartha, F Herting, M Hasmann
International Journal of Cancer|January 21, 1993
Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cellsK Wosikowski, W Küng, M Hasmann, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 7, 2002
Cytoprotective features of selenazofurin in hematopoietic cellsA Pogrebniak, M Hasmann, I Schemainda, et al.
Biochemical Pharmacology|January 15, 1989
Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometryM Hasmann, G K Valet, H Tapiero, et al.
European Journal of Medical Research|November 5, 2003
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effectsA Pogrebniak, I Schemainda, R Pelka-Fleischer, et al.
European Journal of Medical Research|October 21, 2006
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agentsA Pogrebniak, I Schemainda, K Azzam, et al.
Virchows Archiv : an International Journal of Pathology|January 1, 1995
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cellsA Seidel, M Hasmann, R Löser, et al.
Leukemia & Lymphoma|January 28, 1999
In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variantsV Nüssler, R Pelka-Fleisc, F Gieseler, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Letters|September 15, 1994
Preclinical data for DroloxifeneM Hasmann, B Rattel, R Löser
Anticancer Research|November 11, 2006
Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpressionT Friess, W Scheuer, M Hasmann
Pharmacology & Therapeutics|January 14, 2014
Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluationK Wartha, F Herting, M Hasmann
International Journal of Cancer|January 21, 1993
Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cellsK Wosikowski, W Küng, M Hasmann, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 7, 2002
Cytoprotective features of selenazofurin in hematopoietic cellsA Pogrebniak, M Hasmann, I Schemainda, et al.
Biochemical Pharmacology|January 15, 1989
Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometryM Hasmann, G K Valet, H Tapiero, et al.
European Journal of Medical Research|November 5, 2003
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effectsA Pogrebniak, I Schemainda, R Pelka-Fleischer, et al.
European Journal of Medical Research|October 21, 2006
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agentsA Pogrebniak, I Schemainda, K Azzam, et al.
Virchows Archiv : an International Journal of Pathology|January 1, 1995
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cellsA Seidel, M Hasmann, R Löser, et al.
Leukemia & Lymphoma|January 28, 1999
In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variantsV Nüssler, R Pelka-Fleisc, F Gieseler, et al.
Pageof 2